Hutchmed China inks global licensing deal with Takeda on fruquintinib

(Alliance News) - Hutchmed China Ltd on Tuesday said it closed a license agreement with a ...

Alliance News 14 March, 2023 | 2:23PM
Email Form Facebook Twitter LinkedIn RSS

(Alliance News) - Hutchmed China Ltd on Tuesday said it closed a license agreement with a subsidiary of Tokyo-based drug maker Takeda Pharmaceutical Co Ltd for fruquintinib.

Hutchmed China shares were up 6.2% to 236.38 pence each in London on Tuesday afternoon. Takeda Pharmaceutical share closed 0.3% lower at JPY4,280.00 each on Tuesday in Tokyo.

Hutchmed China is a Hong Kong-based treatments of cancer and immunological diseases.

Hutchmed said it will receive USD400 million under the agreement, and will receive up to USD730 million in additional payments, based on the performance of fruquintinib. It added that it expects marketing authorisation submissions in the US, Europe and Japan to complete in 2023, with the rolling submission to the US Food & Drug Administration started in December last year.

Under the agreement, Takeda is "responsible for the development, commercialization and manufacture of fruquintinib in all included territories worldwide excluding mainland China, Hong Kong and Macau, where it is marketed by Hutchmed."

Fruquintinib is an inhibitor of vascular endothelial growth factor receptors and had achieved positive results from a trial in refractory metastatic colorectal cancer. CRC is the third most prevalent cancer worldwide, according to Hutchmed, associated with more than 935,000 deaths in 2020.

By Tom Budszus, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
HUTCHMED (China) Ltd 346.00 GBX -1.14 -
Takeda Pharmaceutical Co Ltd 4,205.00 JPY 2.51

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures